Immunai raises $60 million to analyze the immune system with AI

12 Feb, 2021

Immunai raises $60 million to analyze the immune system with AI
Photo by Dose Media on Unsplash

– Immunai, a startup developing an AI platform to analyze the human immune system, today announced that it raised $60 million.
– The company says it will use the funds to broaden its functional genomics capabilities and help its partners prioritize, discover, and develop new therapies and drug combinations.
– Emerging treatments like gene cell therapies and cancer immunotherapies promise to revolutionize the field of medicine. But the immune system’s complexity — trillions of cells partitioned into hundreds of types and states that interplay with various systems and proteins — threatens to stymie research.
– Immunai aims to prevent such mistakes with immune profile-generating AI.
– The company was founded in 2018 by Noam Solomon, an ex-Harvard and -MIT postdoctoral researcher, and Luis Voloch, an MIT graduate and former machine learning engineer at Palantir.

Artificial Intelligence Biotechnology Machine Learning North America
Crunchbase icon

Content report

The following text will be sent to our editors: